최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국호스피스·완화의료학회지 = Korean journal of hospice and palliative care, v.17 no.1, 2014년, pp.18 - 26
이소진 (고려대학교 의학대학 가정의학교실) , 이준용 (고려대학교 의학대학 가정의학교실) , 최윤선 (고려대학교 의학대학 가정의학교실) , 이준영 (고려대학교 의학대학 통계학교실)
Purpose: Anorexia is a common symptom in terminal cancer patients. Some data have suggested a role of visfatin in regulating feeding behavior. We studied the relationship of a serum visfatin level and anorexia in cancer patients provided with hospice care. Methods: After informed consent was obtaine...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
암성 악액질이란 무엇인가? | 말기암환자는 식욕부진을 흔히 호소하며 전체 암환자의 10∼20%에서 체중 감소로 인한 악액질로 사망한다. 암성 악액질은 암의 직접적인 혹은 간접적인 영향 으로 인하여 지속적인 체중감소(병전 체중의 10% 이상) 와 식욕부진, 지방 조직 및 근육의 쇠퇴, 영양학적 대사 불균형 등을 초래하는 증후군이라고 정의한다(1). | |
싸이토카인의 역할은 무엇인가? | 식이 섭취의 중추 전달 체계를 제어하는 말초 전달 조절자로 ghrelin 같은 호르몬이 존재하 는데 이는 식욕을 자극하는 orexigenic hormone으로 작용하며(11) 식욕을 억제하는 anorexigenic hormone으로 leptin 등이 알려져 있다(12). 이러한 식이 조절 전달 경로에 영향을 주는 대표적 물질이 싸이토카인이며, 이는 손상된 조직에 림프구, 중성구, 단핵구와 그 밖의 손상복구 세포들을 유도하여 손상을 회복시키는데 주된 역할을 한다. 암성 악액질에서 싸이토카인의 기능은 중요한데 tumor necrosis factor-alpha (TNF-α), Interukin-1 (IL-1), Interukin-6 (IL-6), interferon-gamma (INF-γ), 그리고 leukemia inhibitory factor (LIF) 등의 싸이토카인들은 암성 악액 질의 주요 인자로 작용하며 종양이나 정상조직에서 생성되어 식욕부진을 유발한다. | |
비만환자에게 visfatin 수치가 높을 것으로 예상되는 이유는 무엇인가? | Visfatin은 지방조직으로부터 생성, 분비되는 adipokine 중 하나로 52 kDa의 단백으로 피하지방보다는 내장지 방에 많이 존재한다. 따라서 내장지방이 많은 비만환자에서 높을 것으로 생각되는데 비만 여성 92명을 대상으로 한 visfatin 연구에 의하면 비만 환자에서 visfatin 수치는 정상 대조군에 비해 의미 있게 높아져 있었으며(P <0. |
Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 1997;315:1219-22.
Suh SY, Choi YS, Shim JY, Kim YS, Yeom CH, Kim D, et al. Construction of a new, objective prognostic score for terminally ill cancer patients: a multicenter study. Support Care Cancer 2010; 18:151-7.
Chow E, Harth T, Hruby G, Finkelstein J, Wu J, Danjoux C. How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol (R Coll Radiol) 2001;13:209-18.
Vigano A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M. Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer 2004;101:1090-8.
Rosenthal MA, Gebski VJ, Kefford RF, Stuart-Harris RC. Prediction of life-expectancy in hospice patients: identification of novel prognostic factors. Palliat Med 1993;7:199-204.
Bruera E, Miller MJ, Kuehn N, MacEachern T, Hanson J. Estimate of survival of patients admitted to a palliative care unit: a prospective study. J Pain Symptom Manage 1992;7:82-6.
Pirovano M, Maltoni M, Nanni O, Marinari M, Indelli M, Zaninetta G, et al. A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. ltalian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage 1999;17:231-9.
Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004;80:299-307.
Engel JH, Siewerdt F, Jackson R, Akobundu U, Wait C, Sahyoun N. Hardiness, depression, and emotional well-being and their association with appetite in older adults. J Am Geriatr Soc 2011;59:482-7.
Caliskan Y, Yelken B, Gorgulu N, Ozkok A, Yazici H, Telci A, et al. Comparison of markers of appetite and inflammation between hemodialysis patients with and without failed renal transplants. J Ren Nutr 2012;22:258-67.
Robertson MD, Henderson RA, Vist GE, Rumsey RD. Plasma ghrelin response following a period of acute overfeeding in normal weight men. Int J Obes Relat Metab Disord 2004;28:727-33.
Smiechowska J, Utech A, Taffet G, Hayes T, Marcelli M, Garcia JM. Adipokines in patients with cancer anorexia and cachexia. J Iinvesting Med 2010;58:554-9.
Geissbuhler P, Mermillod B, Rapin CH. Elevated serum vitamin B12 levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years. J Pain Symptom Manage 2000;20:93-103.
McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001;41:64-9.
Bottcher Y, Teupser D, Enigk B, Berndt J, Kloting N, Schon MR, et al. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab 2006;91:2725-31.
Blakemore AI, Meyre D, Delplanque J, Vatin V, Lecoeur C, Marre M, et al. A rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from obesity. Obesity (Silver Spring) 2009;17:1549-53.
Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
Olszanecka-Glinianowicz M, Kocelak P, Janowska J, Skorupa A, Nylec M, Zahorska-Markiewicz B. Plasma visfatin and tumor necrosis factor-alpha (TNF- $\alpha$ ) levels in metabolic syndrome. Kardiol Pol 2011;69:802-7.
Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colony enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295-9.
Lajunen TK, Purhonen AK, Haapea M, Ruokonen A, Puukka K, Hartikainen AL, et al. Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. Eur J Clin Invest 2012;42:321-8.
Carrero JJ, Witasp A, Stenvinkel P, Qureshi AR, Heimburger O, Barany P, et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant 2010;25:901-6.
Cline MA, Nandar W, Prall BC, Bowden CN, Denbow DM. Central visfatin causes orexigenic effects in chicks. Behav Brain Res 2008;186:293-7.
Sun G, Bishop J, Khalili S, Vasdev S, Gill V, Pace D, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007;85:399-404.
Kovacikova M, Vitkova M, Klimcakova E, Polak J, Hejnova J, Bajzova M, et al. Visfatin expression in subcutaneous adipose tissue of pre-menopausal women: relation to hormones and weight reduction. Eur J Clin Invest 2008;38:516-22.
Hallschmid M, Randeva H, Tan BK, Kern W, Lehnert H. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diagetes 2009;58:637-40.
Weeks JC, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998;279:1709-14.
Morita T, Tsunoda J, Inoue S, Chihara S. The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 1999;7:128-33.
Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch lntern Med 1988;148:1586-91.
Sungurtekin H, Sungurtekin U, Hanci V, Erdem E. Comparison of two nutrition assessment techniques in hospitalized patients. Nutrition 2004;20:428-32.
Zabel R, Ash S, King N, Bauer J. The relationship between subjective appetite sensations, markers of inflammation and appetite in dialysis patients. J Hum Nutr Diet 2009;22:343-50.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.